Welcome to our dedicated page for Natera news (Ticker: NTRA), a resource for investors and traders seeking the latest updates and insights on Natera stock.
Natera, Inc. develops and commercializes cell-free DNA and genetic testing for oncology, women’s health and organ health. Company updates commonly cover financial results, revenue trends, laboratory operations and publications supporting tests such as Signatera, Prospera, Panorama and Horizon.
Recurring news also includes oncology molecular residual disease applications, clinical evidence presented at medical meetings, transplant rejection surveillance data, collaborations using Natera assays in drug trials, and patent or litigation developments tied to its MRD technology. The company reports through CLIA-certified and CAP-accredited laboratory operations and through Foresight Diagnostics, its subsidiary.
Natera (NASDAQ:NTRA) and CytoDyn (OTCQB:CYDY) announced a strategic collaboration on June 4, 2026 to support leronlimab development in metastatic colorectal cancer (mCRC).
Natera will use its personalized MRD assay Signatera and a large real-world molecular oncology dataset to analyze ctDNA dynamics in samples from CytoDyn’s CLOVER Phase 2 mCRC study.
Natera (NASDAQ:NTRA) appointed leading oncologists Thomas Lynch, M.D. and Eric Rubin, M.D. to its board of directors, effective June 3, 2026.
Dr. Lynch joins the Human Capital Committee, while Dr. Rubin joins the Nominating, Corporate Governance and Compliance Committee, adding extensive oncology, clinical development and precision medicine expertise.
Natera (NASDAQ:NTRA) announced a collaboration with Diakonos Oncology to use its personalized MRD assay Signatera in the DOC-RM Phase I/II trial in refractory melanoma. The study evaluates investigational dendritic cell therapy DOC1021 (dubodencel), which has FDA Fast Track designation in unresectable or metastatic cutaneous melanoma.
Signatera will longitudinally measure circulating tumor DNA at multiple timepoints to assess molecular response and disease dynamics in this high unmet-need population.
Natera (NASDAQ:NTRA) has enrolled the first patients in SIGNAL-ER 101, a prospective, single-arm, multi-center study using Signatera to guide de-escalation of adjuvant CDK4/6 inhibitor therapy in intermediate-risk, HR+/HER2- early breast cancer.
The trial plans to enroll ~725 patients at 50 U.S. sites, assigning CDK4/6 inhibitors based on MRD status and quarterly Signatera monitoring.
Natera (NASDAQ:NTRA) announced an enhanced Panorama NIPT powered by SNP-informed deep sequencing, aimed at improving performance in low fetal fraction samples.
A prospective, blinded study in 3,323 patients, including 242 low fetal fraction or previously no-call samples, showed 100% sensitivity for trisomy 21 and 13, 93.3% for trisomy 18, and a reduced no-call rate of 0.5%, with all outcomes confirmed by diagnostic genetic testing.
Natera (NASDAQ:NTRA) will present 35 oncology studies, including 3 oral talks, at the 2026 ASCO meeting in Chicago.
Data feature Signatera-based MRD testing in colorectal cancer, a large pan-cancer meta-analysis, ultrasensitive phased variant technology across solid and blood cancers, plus new real-world evidence and an Annotation digital platform.
Natera (NASDAQ:NTRA) announced a major expansion at its North Austin headquarters, adding a dedicated sequencing facility and new lab space to support rapid growth.
The facility is expected to have the largest sequencing capacity in the world, meeting rising demand, especially in oncology, where testing volumes grew over 54% year-over-year in Q1 2026.
Natera’s Signatera test is used by more than 50% of U.S. oncologists, and Signatera CDx recently became the first FDA-approved companion diagnostic in molecular residual disease testing. The expansion is expected to create up to 400 new jobs across professional, laboratory, and operational roles while supporting hundreds of ongoing clinical trials and research collaborations.
Natera (NASDAQ:NTRA) reported that the EXPAND clinical trial of its Fetal Focus™ single-gene noninvasive prenatal test (NIPT) has enrolled over 2,000 patients, more than doubling enrollment in the past 12 months.
EXPAND is a prospective, blinded, multi-site study assessing Fetal Focus, which evaluates 21 genes linked to serious, early-onset conditions and uses LinkedSNP™ technology. Early EXPAND data showed strong clinical performance and accurate detection in 5 of 5 difficult homozygous cases.
Natera (NASDAQ:NTRA) announced FDA approval of Signatera CDx as a companion diagnostic for adjuvant atezolizumab (Tecentriq) immunotherapy in muscle-invasive bladder cancer (MIBC). This is the first FDA-approved blood-based MRD companion diagnostic.
According to Natera, IMvigor011 Phase III data showed MRD-positive patients on immunotherapy had improved DFS and OS, while MRD-negative patients achieved 97% 2-year OS without adjuvant therapy. Signatera is supported by 185+ publications and Medicare coverage across multiple cancer types.
Natera (NASDAQ: NTRA) reported Q1 2026 results: $696.6M revenue, up 38.8% year-over-year; processed 1,013,600 tests (up 18.5%); gross margin of 64.7%. Oncology tests rose 54.4% to 258,900. Net loss was $85.1M (−$0.60/share). Company raised 2026 revenue guidance to $2.74B–$2.82B and expects positive net cash inflow.